Wellington Management Group
TBPH icon

Wellington Management Group’s Theravance Biopharma TBPH Stock Holding History

Wellington Management Group’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.78M Sell
109,700
-13,265
-11% -$235K ﹤0.01% 1574
2025
Q4 		$2.3M Sell
122,965
-7,186
-6% -$119K ﹤0.01% 1566
2025
Q3 		$1.9M Sell
130,151
-37,278
-22% -$471K ﹤0.01% 1647
2025
Q2 		$1.85M Buy
167,429
+12,000
+8% +$117K ﹤0.01% 1595
2025
Q1 		$1.39M Sell
155,429
-43,062
-22% -$401K ﹤0.01% 1635
2024
Q4 		$1.87M Buy
198,491
+7,162
+4% +$65.2K ﹤0.01% 1583
2024
Q3 		$1.54M Sell
191,329
-159,258
-45% -$1.38M ﹤0.01% 1617
2024
Q2 		$2.97M Buy
350,587
+19,625
+6% +$177K ﹤0.01% 1430
2024
Q1 		$2.97M Buy
330,962
+43,860
+15% +$406K ﹤0.01% 1445
2023
Q4 		$3.23M Buy
287,102
+116,164
+68% +$1.17M ﹤0.01% 1401
2023
Q3 		$1.48M Sell
170,938
-11,322
-6% -$109K ﹤0.01% 1534
2023
Q2 		$1.89M Buy
182,260
+41,999
+30% +$464K ﹤0.01% 1489
2023
Q1 		$1.52M Sell
140,261
-3,171
-2% -$33.5K ﹤0.01% 1562
2022
Q4 		$1.61M Sell
143,432
-8,078
-5% -$84.9K ﹤0.01% 1547
2022
Q3 		$1.54M Buy
151,510
+4,042
+3% +$37.9K ﹤0.01% 1575
2022
Q2 		$1.34M Sell
147,468
-919
-0.6% -$8.47K ﹤0.01% 1618
2022
Q1 		$1.42M Sell
148,387
-49,667
-25% -$487K ﹤0.01% 1675
2021
Q4 		$2.19M Sell
198,054
-52,165
-21% -$455K ﹤0.01% 1643
2021
Q3 		$1.85M Sell
250,219
-8,477,105
-97% -$94.8M ﹤0.01% 1695
2021
Q2 		$127M Buy
8,727,324
+1,263,122
+17% +$23.7M 0.02% 568
2021
Q1 		$152M Buy
7,464,202
+1,996,902
+37% +$38M 0.03% 487
2020
Q4 		$97.2M Buy
5,467,300
+739,708
+16% +$13.3M 0.02% 598
2020
Q3 		$69.9M Buy
4,727,592
+244,815
+5% +$4.59M 0.01% 606
2020
Q2 		$94.1M Buy
4,482,777
+315,254
+8% +$8.1M 0.02% 541
2020
Q1 		$96.3M Buy
4,167,523
+989,986
+31% +$24.8M 0.03% 467
2019
Q4 		$82.3M Buy
+3,177,537
New +$61.8M 0.02% 615
2016
Q4 		– Sell
-190,950
Closed -$6.92M – 2266
2016
Q3 		$6.92M Buy
+190,950
New +$5.32M ﹤0.01% 1287

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group's TBPH Position: Q1 2026 in Review

Wellington Management Group reduced its Theravance Biopharma (TBPH) stake by 11% in Q1 2026, selling an estimated $235K and leaving 109,700 shares worth $1.78M. The position accounts for ﹤0.01% of the portfolio, ranked #1574.

Wellington Management Group first reported a position in TBPH in Q3 2016 and has held it in 27 quarters since. The position peaked at $152M in Q1 2021. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Wellington Management Group held 109,700 shares of Theravance Biopharma worth $1.78M as of Q1 2026.
  • Wellington Management Group sold 13,265 Theravance Biopharma shares in Q1 2026, an estimated $235K.
  • Theravance Biopharma made up ﹤0.01% of Wellington Management Group's portfolio in Q1 2026, its #1574 holding.
  • Wellington Management Group first reported a position in Theravance Biopharma in Q3 2016 and has held it in 27 quarters since.
  • Wellington Management Group's Theravance Biopharma position peaked at $152M in Q1 2021.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Wellington Management Group's 13F filing for Q1 2026, filed 15 May 2026.